When was Atum founded?

Atum was founded in 2003 and raised its 1st funding round 5 years after it was founded.

Where is Atum located?

Atum is headquartered in Newark, United States. It is registered at Newark, California.

How many employees does Atum have?

As of Aug 31, 2026, the latest employee count at Atum is 142.

Is Atum a funded company?

Atum is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 14, 2008.

When was the latest funding round of Atum?

Atum's latest funding was a $***** Grant (prize money) round on Feb 07, 2011, with participation from 1 investor.

Where does Atum rank among its competitors?

Atum ranks 220th amongst 2934 active competitors, of which 820 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Tango Therapeutics, which secured $15M in Oct, 2025.

Who are the top competitors of Atum?

Atum's top competitors include Ginkgo Bioworks, Alnylam and Syngenta. Among them, Tango Therapeutics secured the most recent funding round in October, 2025.

Atum - 2026 Company Profile, Funding & Competitors

Company Details

Integrated life science solutions accelerating discovery to manufacturing for genes, antibodies, cell lines. They provide integrated solutions to accelerate timelines from discovery to manufacturing, and preclinical research to IND applications. They offer services in gene design and synthesis, antibody services, cell line development, protein expression, and biological engineering. Their expertise includes analytics, assay development, codon optimization, and expression testing. They provide resources like gene designer, literature database, and DNA atlas. They offer catalog orders for expression vectors, CRISPR/Cas9, and reagents. They focus on collaboration, combining their expertise with clients' expertise for mutual success. They are a one-stop shop with expertise in machine learning, gene synthesis, protein expression and cell line development. They provide tools and solutions to life science researchers, enabling scientists worldwide to achieve their goals. They offer software tool Gene Designer and the online DNA ATLAS, giving DNA sequence manipulation and management tools.

Website: www.atum.bio/
Social
Registered Address: Newark, California

Key Metrics

Founded Year

2003

Location

Newark, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Feb 07, 2011, $*****

Investors

National Science Foundation

Ranked

220^th among 2934 active competitors

Employee Count

142 as on Aug 31, 2026

Investment & Acquisitions

Vernal Biosciences & 1 more

Similar Companies

Ginkgo Bioworks & 2856 more

View Atum's full profile

Atum is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
DNA 2.0, INC. CIN: 743076460 , United States, Active	Dec 31, 1999	-	139 (As on Dec 31, 2024)	-

Atum has raised funding over 2 rounds. Its first funding round was on Mar 14, 2008. Its latest funding round was a Grant (prize money) round on Feb 07, 2011 for $*****. 1 investor participated in its latest round. Atum has 1 institutional investor.

Here is the list of recent funding rounds of Atum:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 07, 2011	6876185	Grant (prize money)	8082944	9249530	6549683	2796402
Mar 14, 2008	4887137	Grant (prize money)	2658299	1176439	4827328	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of Atum's funding rounds and investors

Atum's employee count trend

Atum has 142 employees as of Aug 26. Here is Atum's employee count trend over the years:

Uncover Atum's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Atum include Ginkgo Bioworks, Alnylam and Syngenta. Here is the list of Top 10 competitors of Atum, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	72/100
6th	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
7th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
8th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
9th	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	70/100
10th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
220th	Atum 2003, Newark (United States), Funding Raised	Integrated life science solutions accelerating discovery to manufacturing for genes, antibodies, cell lines	-	National Science Foundation	53/100